Dovato Matches Biktarvy in Head-to-Head Trial-but Gilead's HIV Lead Still Looks Big

DYAD supports Dovato in a defined switch population

Dovato matched Biktarvy in a head-to-head trial, even as Biktarvy continued to grow.

That is why the data matter. ViiV is presenting the largest head-to-head RCT of Dovato versus Biktarvy, and the results point to a meaningful role for two-drug simplification in patients who are already suppressed on Biktarvy. Even so, one positive trial does not by itself prove that Biktarvy's market position is materially weaker.

The bigger issue may be behavioral, not clinical. Gilead still has real defensive power because Biktarvy posted 7% growth in 2025 and holds more than 52% market share. A leader still expanding like that is unlikely to lose meaningful ground from one trial alone. But dominance can become more vulnerable the moment a credible equalizer appears, because prescribers do not always need superior efficacy to switch; sometimes they only need evidence that switching is safe enough.

Why the results are encouraging for Dovato-but still limited

DYAD answered a narrow question

The key limit is scope. Encouraging is the right word, not broad.

What DYAD actually showed

DYAD was set up as a rigorous head-to-head, randomized noninferiority trial with a 6% noninferiority margin and a Week 48 primary endpoint in adults who had been virologically suppressed on Biktarvy for at least 3 months. That is a clean question: can people who are stable on Biktarvy switch to a two-drug regimen without an unacceptable risk of virologic failure? It is not the same as showing Dovato is equivalent to Biktarvy across the full HIV treatment pathway.

The population helps explain why. Participants had been suppressed on Biktarvy for at least 3 months, with at least two documented measurements of suppression, no prior viral failure, and no documented integrase or major nucleoside resistance. In practical terms, DYAD tested simplification in a low-risk group, not initial treatment choice. That makes the results positive for a specific clinical decision, but narrower than many readers will assume.

The evidence base is wider than one switch trial

That narrower win fits into a larger portfolio story. ViiV is also showing VOGUE, the first head-to-head randomised daily orals study comparing Dovato with Biktarvy in treatment-naïve adults. That matters because new-start patients are the real greenfield battleground for first-line therapy. If two-drug simplification is going to challenge Biktarvy at scale, it eventually needs support in that population as well.

The competitive field is also broader than daily pill reduction. ViiV is presenting OPERA real-world data on CAB+RPV LA versus daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir, which pushes the debate beyond "fewer pills is better." Long-acting therapy changes the preference stack in a different way.

Why prescribing can stay sticky

Noninferiority answers one statistical question; it does not force adoption. Prescribers tend to anchor on the current standard, especially when they believe they are protecting a patient from relapse. The perceived downside of virologic failure can outweigh the benefit of simplification, even when the trial suggests the risk is acceptable.

Earlier durability signals help the overall dataset look coherent. ViiV has highlighted 96-week findings from PASO DOBLE showing Dovato remained effective through two years of follow-up in switched patients. But actual adoption will still depend on how much weight clinicians give to head-to-head evidence versus habit, liability concerns, and the preference to leave an effective regimen unchanged.

For investors, the takeaway is narrow but important: the data strengthen the case for Dovato as a credible simplification option in a defined population, but they do not yet prove a broad shift away from Biktarvy.